Pursuit Vascular Achieves Milestone with Shipment of 2 Millionth Pair of ClearGuard® HD Caps
Published: Jul 10, 2018
MAPLE GROVE, Minn., July 10, 2018 /PRNewswire/ -- Pursuit Vascular, Inc. manufacturer of ClearGuard® HD Antimicrobial Barrier Caps, the leading antimicrobial device for catheter-based dialysis patients, reached a milestone in June with the shipment of over 2 million pairs of ClearGuard HD caps during the first 6 months of 2018, an important achievement as the company continues to bring its innovative technology to a broader patient base. The product is manufactured at the company's headquarters in Maple Grove, Minnesota.
The ClearGuard HD cap is the first and only device cleared for sale in the US that kills infection-causing bacteria inside a long-term catheter hub. The company recently received expanded FDA indications to include reduction of central-line associated bloodstream infection (CLABSI) in hemodialysis patients with central venous catheters (CVCs).
Major studies with more than 4000 total hemodialysis patients in 80 centers showed up to a 69% lower rate of bloodstream infection using ClearGuard HD caps vs. commonly used caps.1-2 ClearGuard HD caps enable dialysis providers to protect patients receiving dialysis via CVC against costly and potentially deadly infections. Bloodstream infection is the leading cause for hospitalizations and the second leading cause of death in hemodialysis patients, with catheters causing 70% of these infections.
"We are excited to reach this milestone as a company. We are seeing accelerated adoption of ClearGuard HD caps in hospitals and dialysis facilities across the US," said Doug Killion, President and CEO of Pursuit Vascular. "Because ClearGuard HD caps replace existing caps and connectors, they are easy to implement and are quickly becoming the standard of care. We are committed to enabling more patients to benefit from the benefits of ClearGuard HD caps and look forward to sharing additional milestones in the future."
1Brunelli, SM et al. Cluster-Randomized Trial of Devices to Prevent Catheter-Related Bloodstream Infection. J Am Soc Nephrol. 2018;19:1336-43.
2Hymes, JL et al. Dialysis Catheter-Related Bloodstream Infections: A Cluster-Randomized Trial of the ClearGuard HD Antimicrobial Barrier Cap. Am J Kidney Dis. 2017;69:220-7.
About the ClearGuard HD Antimicrobial Barrier Cap
The ClearGuard HD Antimicrobial Barrier Cap is the first and only device cleared for sale in the U.S. that kills infection-causing bacteria inside a long-term hemodialysis catheter hub. The caps are simple to use and clinically shown to reduce central line-associated bloodstream infection. This simple, yet revolutionary single-use device is protected by 7 issued U.S. patents, and several other U.S. patents pending. Foreign patents issued and pending. For more information, visit www.clearguardhd.com
About Pursuit Vascular
Headquartered in Maple Grove, Minnesota, Pursuit Vascular, Inc. (www.pursuitvascular.com) is developing a family of innovative products designed to protect patients from acquiring life-threatening infections associated with long-term catheter and port use, while reducing the costs of health care.
Connect with us at www.pursuitvascular.com and on Twitter at @ClearGuardHD.
View original content with multimedia:http://www.prnewswire.com/news-releases/pursuit-vascular-achieves-milestone-with-shipment-of-2-millionth-pair-of-clearguard-hd-caps-300678111.html
SOURCE Pursuit Vascular